Literature DB >> 34006860

Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy.

Chi Zhang1, Ziling Zeng1, Dong Cui1, Shasha He1, Yuyan Jiang1, Jingchao Li1, Jiaguo Huang1, Kanyi Pu2,3.   

Abstract

Immunometabolic intervention has been applied to treat cancer via inhibition of certain enzymes associated with intratumoral metabolism. However, small-molecule inhibitors and genetic modification often suffer from insufficiency and off-target side effects. Proteolysis targeting chimeras (PROTACs) provide an alternative way to modulate protein homeostasis for cancer therapy; however, the always-on bioactivity of existing PROTACs potentially leads to uncontrollable protein degradation at non-target sites, limiting their in vivo therapeutic efficacy. We herein report a semiconducting polymer nano-PROTAC (SPNpro) with phototherapeutic and activatable protein degradation abilities for photo-immunometabolic cancer therapy. SPNpro can remotely generate singlet oxygen (1O2) under NIR photoirradiation to eradicate tumor cells and induce immunogenic cell death (ICD) to enhance tumor immunogenicity. Moreover, the PROTAC function of SPNpro is specifically activated by a cancer biomarker (cathepsin B) to trigger targeted proteolysis of immunosuppressive indoleamine 2,3-dioxygenase (IDO) in the tumor of living mice. The persistent IDO degradation blocks tryptophan (Trp)-catabolism program and promotes the activation of effector T cells. Such a SPNpro-mediated in-situ immunometabolic intervention synergizes immunogenic phototherapy to boost the antitumor T-cell immunity, effectively inhibiting tumor growth and metastasis. Thus, this study provides a polymer platform to advance PROTAC in cancer therapy.

Entities:  

Year:  2021        PMID: 34006860     DOI: 10.1038/s41467-021-23194-w

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  17 in total

Review 1.  Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy.

Authors:  Lixia Chen; Xinqiang Wan; Xiangxiang Shan; Wenzhang Zha; Rengen Fan
Journal:  Mol Diagn Ther       Date:  2022-04-26       Impact factor: 4.074

Review 2.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 3.  Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.

Authors:  Yu Chen; Ira Tandon; William Heelan; Yixin Wang; Weiping Tang; Quanyin Hu
Journal:  Chem Soc Rev       Date:  2022-07-04       Impact factor: 60.615

4.  An in situ hydrogel-mediated chemo-immunometabolic cancer therapy.

Authors:  Bo Wang; Jing Chen; Julia S Caserto; Xi Wang; Minglin Ma
Journal:  Nat Commun       Date:  2022-07-02       Impact factor: 17.694

5.  Cascade-activatable NO release based on GSH-detonated "nanobomb" for multi-pathways cancer therapy.

Authors:  Yi Feng; Hanxi Zhang; Xiaoxue Xie; Yu Chen; Geng Yang; Xiaodan Wei; Ningxi Li; Mengyue Li; Tingting Li; Xiang Qin; Shun Li; Fengming You; Chunhui Wu; Hong Yang; Yiyao Liu
Journal:  Mater Today Bio       Date:  2022-05-13

6.  Ultrasound-Controlled CRISPR/Cas9 System Augments Sonodynamic Therapy of Hepatocellular Carcinoma.

Authors:  Haohao Yin; Liping Sun; Yinying Pu; Jifeng Yu; Wei Feng; Caihong Dong; Bangguo Zhou; Dou Du; Yan Zhang; Yu Chen; Huixiong Xu
Journal:  ACS Cent Sci       Date:  2021-12-08       Impact factor: 14.553

7.  Engineered extracellular vesicle-based sonotheranostics for dual stimuli-sensitive drug release and photoacoustic imaging-guided chemo-sonodynamic cancer therapy.

Authors:  Thuy Giang Nguyen Cao; Ji Hee Kang; Wangyu Kim; Junha Lim; Su Jin Kang; Jae Young You; Quan Truong Hoang; Won Jong Kim; Won Jong Rhee; Chulhong Kim; Young Tag Ko; Min Suk Shim
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.556

8.  Trojan Horse-Like Nano-AIE Aggregates Based on Homologous Targeting Strategy and Their Photodynamic Therapy in Anticancer Application.

Authors:  Yin Li; Rongyuan Zhang; Qing Wan; Rong Hu; Yao Ma; Zhiming Wang; Jianquan Hou; Weijie Zhang; Ben Zhong Tang
Journal:  Adv Sci (Weinh)       Date:  2021-10-20       Impact factor: 16.806

9.  Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy.

Authors:  Tingting Wang; Hao Zhang; Weibao Qiu; Yaobao Han; Hanghang Liu; Zhen Li
Journal:  Bioact Mater       Date:  2022-01-05

10.  Arsenene-mediated multiple independently targeted reactive oxygen species burst for cancer therapy.

Authors:  Na Kong; Hanjie Zhang; Chan Feng; Chuang Liu; Yufen Xiao; Xingcai Zhang; Lin Mei; Jong Seung Kim; Wei Tao; Xiaoyuan Ji
Journal:  Nat Commun       Date:  2021-08-06       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.